Intellectual property (IP). © patent ™ © ™ i. theory.
-
Upload
maximilian-white -
Category
Documents
-
view
216 -
download
2
Transcript of Intellectual property (IP). © patent ™ © ™ i. theory.
![Page 1: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/1.jpg)
Intellectual
property(IP)
![Page 2: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/2.jpg)
©patent ™
![Page 3: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/3.jpg)
patent © ™
![Page 4: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/4.jpg)
i. theory
![Page 5: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/5.jpg)
Aha!new?
useful?
not
obvious?
![Page 6: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/6.jpg)
“static inefficiency”
![Page 7: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/7.jpg)
“dynamic inefficiency
”
![Page 8: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/8.jpg)
![Page 9: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/9.jpg)
ii. practice
![Page 10: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/10.jpg)
LopinavirRitonavir ++
![Page 11: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/11.jpg)
U.S.A., Botswana, India
![Page 12: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/12.jpg)
U.S.A., Botswana, India
![Page 13: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/13.jpg)
![Page 14: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/14.jpg)
...andProcess
Number Relevant Claim1991
5,648,497 RTV molecule Product New Chemical Entity
1993
5,674,882 use of RTV with a PI for HIV Use 5,635,523 use of RTV with an RTI for
inhibiting HIVUse
5,541,206 use of RTV for inhibiting HIV Use 5,846,987 combination of RTV and an RTI
ProductCombination
5,886,036 combination of RTV and a PI Product Combination1996
5 ,037,157
use of RTV to boost a PI Use
6,703,403 use of RTV to inhibit cytochrome P450 monoxygenase
Use
1996
5,914,332 LPV molecule Product New Chemical Entity
6,284,767 use of LPV with RTIs or PIs Use 1997
6,232,333 soft-gel formulation of RTV Product Formulation 6,458,818 soft-gel formulation of RTV &
LPVProduct Formulation
6,521,651 soft-gel formulation of LPV Product Formulation
*
*
![Page 15: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/15.jpg)
Others
$2.5 billion
![Page 16: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/16.jpg)
...andProcess
Number Relevant Claim1991
5,648,497 RTV molecule Product New Chemical Entity
1993
5,674,882 use of RTV with a PI for HIV Use 5,635,523 use of RTV with an RTI for
inhibiting HIVUse
5,541,206 use of RTV for inhibiting HIV Use 5,846,987 combination of RTV and an RTI
ProductCombination
5,886,036 combination of RTV and a PI Product Combination1996
5 ,037,157
use of RTV to boost a PI Use
6,703,403 use of RTV to inhibit cytochrome P450 monoxygenase
Use
1996
5,914,332 LPV molecule Product New Chemical Entity
6,284,767 use of LPV with RTIs or PIs Use 1997
6,232,333 soft-gel formulation of RTV Product Formulation 6,458,818 soft-gel formulation of RTV &
LPVProduct Formulation
6,521,651 soft-gel formulation of LPV Product Formulation
*
*
$$
![Page 17: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/17.jpg)
Bayh Dole Act
![Page 18: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/18.jpg)
U.S.A., Botswana, India
![Page 19: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/19.jpg)
U.S.A., Botswana, India
![Page 20: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/20.jpg)
...andProcess
Number Relevant Claim1991
5,648,497 RTV molecule Product New Chemical Entity
1993
5,674,882 use of RTV with a PI for HIV Use 5,635,523 use of RTV with an RTI for
inhibiting HIVUse
5,541,206 use of RTV for inhibiting HIV Use 5,846,987 combination of RTV and an RTI
ProductCombination
5,886,036 combination of RTV and a PI Product Combination1996
5 ,037,157
use of RTV to boost a PI Use
6,703,403 use of RTV to inhibit cytochrome P450 monoxygenase
Use
1996
5,914,332 LPV molecule Product New Chemical Entity
6,284,767 use of LPV with RTIs or PIs Use 1997
6,232,333 soft-gel formulation of RTV Product Formulation 6,458,818 soft-gel formulation of RTV &
LPVProduct Formulation
6,521,651 soft-gel formulation of LPV Product Formulation
*
*
1995
![Page 21: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/21.jpg)
TRIPs
![Page 22: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/22.jpg)
...andProcess
Number Relevant Claim1991
5,648,497 RTV molecule Product New Chemical Entity
1993
5,674,882 use of RTV with a PI for HIV Use 5,635,523 use of RTV with an RTI for
inhibiting HIVUse
5,541,206 use of RTV for inhibiting HIV Use 5,846,987 combination of RTV and an RTI
ProductCombination
5,886,036 combination of RTV and a PI Product Combination1996
5 ,037,157
use of RTV to boost a PI Use
6,703,403 use of RTV to inhibit cytochrome P450 monoxygenase
Use
1996
5,914,332 LPV molecule Product New Chemical Entity
6,284,767 use of LPV with RTIs or PIs Use 1997
6,232,333 soft-gel formulation of RTV Product Formulation 6,458,818 soft-gel formulation of RTV &
LPVProduct Formulation
6,521,651 soft-gel formulation of LPV Product Formulation
*
*
1995
![Page 23: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/23.jpg)
...andProcess
Number Relevant Claim1991
5,648,497 RTV molecule Product New Chemical Entity
1993
5,674,882 use of RTV with a PI for HIV Use 5,635,523 use of RTV with an RTI for
inhibiting HIVUse
5,541,206 use of RTV for inhibiting HIV Use 5,846,987 combination of RTV and an RTI
ProductCombination
5,886,036 combination of RTV and a PI Product Combination1996
5 ,037,157
use of RTV to boost a PI Use
6,703,403 use of RTV to inhibit cytochrome P450 monoxygenase
Use
1996
5,914,332 LPV molecule Product New Chemical Entity
6,284,767 use of LPV with RTIs or PIs Use 1997
6,232,333 soft-gel formulation of RTV Product Formulation 6,458,818 soft-gel formulation of RTV &
LPVProduct Formulation
6,521,651 soft-gel formulation of LPV Product Formulation
*
*
1995
![Page 24: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/24.jpg)
Number Relevant Claim1996
5,914,332LPV molecule Product New Chemical Entity
*
![Page 25: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/25.jpg)
Others
![Page 26: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/26.jpg)
Others
$Pre - 2005
![Page 27: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/27.jpg)
U.S.A., Botswana, India
![Page 28: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/28.jpg)
U.S.A., Botswana, India
![Page 29: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/29.jpg)
...andProcess
Number Relevant Claim1991
5,648,497 RTV molecule Product New Chemical Entity
1993
5,674,882 use of RTV with a PI for HIV Use 5,635,523 use of RTV with an RTI for
inhibiting HIVUse
5,541,206 use of RTV for inhibiting HIV Use 5,846,987 combination of RTV and an RTI
ProductCombination
5,886,036 combination of RTV and a PI Product Combination1996
5 ,037,157
use of RTV to boost a PI Use
6,703,403 use of RTV to inhibit cytochrome P450 monoxygenase
Use
1996
5,914,332 LPV molecule Product New Chemical Entity
6,284,767 use of LPV with RTIs or PIs Use 1997
6,232,333 soft-gel formulation of RTV Product Formulation 6,458,818 soft-gel formulation of RTV &
LPVProduct Formulation
6,521,651 soft-gel formulation of LPV Product Formulation
*
*
![Page 30: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/30.jpg)
Number Relevant Claim
![Page 31: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/31.jpg)
Others
Others (Imports)
![Page 32: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/32.jpg)
Doha Declaration
![Page 33: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/33.jpg)
August 30th Decision
![Page 34: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/34.jpg)
Canadian Access to Medicine
Regime
![Page 35: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/35.jpg)
First application of the CAMR
•May 2004 – CAMR created•Sept 2007 –compulsory license issued for Canada to export HIV/AIDS triple therapy to Rwanda
•May 2008 – Apotex awarded contract
•Sept 2008 – first shipment en route
![Page 36: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/36.jpg)
Failure of the CAMR
“When we order medicines normally, all we need to do is type up a form, send it to the supplier and pay the bill - then we receive the shipment. With this system we have to persuade a government to notify the WTO, find a company willing to produce, push to get a drug on the list of eligible medicines, waitfor voluntary license negotiations to be completed, wait for the compulsory license application to be
made, and then granted.... For a disease that kills 8,000 people a day …
this isnot a solution, it's unacceptable”
Dr. Felipe Garcia de la Vega, MSF
![Page 37: Intellectual property (IP). © patent ™ © ™ i. theory.](https://reader036.fdocuments.us/reader036/viewer/2022070410/56649f1f5503460f94c37ada/html5/thumbnails/37.jpg)
A huge thanksto Michael Steffan for putting this presentation together